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Summary.-The HT29R colonic adenocarcinoma xenograft has been shown to be
rich in the enzyme p-glucuronidase. Experiments in rodent systems have demon-
strated a marked anti-tumour effect of the drug aniline mustard (AM) on tumours
with high levels of this enzyme (e.g. the plasmacytomas PC5 and PC6).
We have found that AM is no more effective than its analogue paramethyl aniline
mustard (PMAM) or other alkykating agents against the HT29R xenograft.
Amongst the possible explanations for this may be:
(1) The wide shoulder on the cell-survival curve shown for exposure to alkylating
agents of HT29R in vivo.
(2) Lack of correlation between physiological availability of P-glucuronidase and the
high levels measured by the standard assay.
(3) Increased p-glucuronidase levels in host mouse marrow, making the latter
potentially more susceptible to AM damage.
ONE APPROACH TO THE problem of the
lack of selectivity of cytotoxic drugs has
been to attempt to synthesize agents
which are activated more efficiently in
tumours than in normal tissues (Harper,
1959; Ross, 1974; Workman & Double,
1978). The rational design of such
latent anti-tumour agents, however, has
been hindered by the lack of appropriate
information on the comparative bio-
chemistry of such vital normal tissues as
marrow and intestinal mucosa (Workman
& Double, 1978). Also, until recently, only
animal tumours have been available for
the pre-clinical development and testing
of these agents. However, human tumour
xenografts now provide a potentially
more relevant system for investigating the
mechanisms of biochemical selectivity of
chemotherapeutic agents. Such experi-
ments in these systems, however, are
necessarily conducted against the back-
ground of mouse biochemistry and phar-
macokinetics.
A frequently cited example of bio-
chemical selectivity is seen with the alkyl-
ating agent aniline mustard (N,N-p-di-2-
chloroethylaniline; AM). This drug
has been shown to be particularly active
against tumours with high levels of the
enzyme /3-glucuronidase in animal sys-
tems such as the ADJ/PC5 mouse plasma-
cell tumour, normally fairly resistant to
alkylating agents (Whisson & Connors,
1965a, b; Connors & Whisson, 1966) and
the HT67 mouse adenocarcinoma
(Double & Workman, 1977).
The proposed mechanism of action
involves conversion to aniline mustard
glucuronide in the liver, followed by
selective release of the highly toxic p-
hydroxy-aniline mustard in tumours rich
in /-glucuronidase (Connors & Whisson,
1966; Connors et al., 1973).
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Despite its activity against plasma-cell
tumours in the laboratory, AM was less
effective than melphalan against myelo-
matosis in man (Healy, 1968; Kyle et al.,
1973). When used against breast, renal
and prostatic tumours, the clinical res-
ponse to AM showed some correlation with
a histochemical estimate of fl-glucuroni-
dase activity (Young et al., 1976) but
because of the small number of responses
further clinical studies have not been
made. AM thus appears to be a drug of
striking biochemical selectivity in certain
laboratory tumours which has been dis-
appointing in its clinical efficacy. Further
investigation of AM in human tumour
xenografts may be useful in two ways.
(1) Features may be found in the response
of the xenograft model tumour to AM
which would explain its poor clinical
performance.
(2) The response of the model to AM may
yield information about the validity
of xenograft tumour models for in-
vestigating biochemical selectivity.
MATERIALS AND METHODS
Drugs.-AM andp-methylaniline mustard
(N,N-p-di-2-chloroethyltoluene; p-methyl
AM) were synthesized at the Chester Beatty
Research Institute and were gifts from
Professor W. C. J. Ross, Dr T. A. Connors, Dr
D. E. V. Wilman and Mr J. L. Everett. They
were dissolved in arachis oil by ultrasonica-
tion (MSE PG-100 ultrasonic disintegrator,
Mk 2). Cyclophosphamide (2-(di(2-chloro-
ethyl)amino-1-oxa-3-aza-2-phosphacyclohex-
ane); Endoxana, W.B. Pharmaceuticals),
was dissolved in phosphate buffered saline
(PBS). Melphalan ((N,N-p-di-2-chloroethyl-
aminophenylalanine); Alkeran Injection,
Wellcome) was dissolved in 10% acidified
ethanol/propylene glycol-K2HPO4 buffer.
Drug solutions were prepared immediately
before use and injected i.p. in a volume of
0-01 ml/g body weight. Controls received
vehicle alone. Drugs were tested at maximum
tolerated dose (no more deaths than in con-
trol group and less than 15% weight loss) and
at lower doses.
Animals.-Male CBA mice were obtained
from O.L.A.C. 1976 (Shaws Farm, Black-
thorne, Bicester). They were immuno-sup-
pressed by a modification of the method of
Kopper & Steel (1975) as previously des-
cribed (Warenius et at., 1980). Mice were
thymectomized at 4 weeks of age and given
9-2 Gy whole-body irradiation from a 60Co
unit 2 weeks later. These animals were re-
constituted within 12 h by 2 x 105 syngeneic
nucleated marrow cells. Nude mice were
kindly given by Dr L. N. Owen, Department
of Clinical Veterinary Medicine, Cambridge.
Tumour8.-The HT29R human colonic
adenocarcinoma (Warenius et al., 1980) is a
once-recloned variant of HT29 (Von Kleist
et at., 1975). The use of this tumour as a
xenograft model system has already been
described (Warenius & Bleehen, submitted).
Anti-tumour effects were determined by com-
paring growth curves of treated and control
tumours. Caliper measurements of in vivo
tumours were made every 3 days, and tumour
volumes calculated as 7r/6 (mean diameter)3.
This formula was chosen because previous
experiments had shown that tumour volumes
calculated thus gave a linear correlation with
the mass of the same tumour when excised
(Warenius 1980b). Chemotherapy experi-
ments were initiated when the mean tumour
volumes were 100-150 mm3. Comparability
oftreated and control groups was ensured by
stratification into 3 groups 50-100, 100-150,
150-200 mm3. From each ofthese size ranges
equal numbers of animals were randomly
allocated to treatment and control groups.
Changes in tumour volume were expressed
by the relative tumour volume (RTV) for
eachtumour onDay t compared to its volume
on the first day of chemotherapy (Day 0).
Solid tumours were disaggregated by
mechanical agitation of tumour brei in a
disaggregating mixture of trypsin 0.5% w/v,
DNase 0-2 mg/ml, plus EDTA 0-025% w/v
in PBS. Thedisaggregated cell suspension was
filtered through a sterile gauze to remove
large clumps and a single-cell suspension was
then obtained by drawing up and down x 3
through a 23-gauge needle. All manipulations
were conducted under sterile conditions.
The cells were counted and adjusted to a
concentration of multiples of 500/ml in
Ham's F12 medium supplemented with 15%
foetal calf serum and 1 ml of the relevant
cell suspension introduced into 4 ml of the
same medium in tissue-culture grade sterile
disposable plastic Petri dishes (Sterilin
50mm triple-vent No. 302V). Cells were
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incubated at 37°C in 50o CO2 for 18 days and
then fixed in ethanol, stained with Giemsa
and clones with 50 or more cells counted as
positive.
Preparation of honmogenates.-HT29R in
vivo tumours were excised and placed im-
mediately on ice. The tumours were then
weighed and distilled water at 4°C was added
to give 10% w,/v. The tumour was then
mechanically homogenized ("Verso" labora-
tory mixer emulsifier, Silverson Machines
Ltd, Waterside, Chesham, Bucks) whilst still
on ice. The homogenate was spun at 300 g
on a MSE6L centrifuge for 10 min at 4°C.
The supernatant was removed, diluted
(usually to give a 10% w/v homogenate) kept
on ice and used to provide 100lul aliquots for
3-glueuronidase estimation. Liver homo-
genates were prepared in a similar manner to
that described for tumour. Small-intestine
mucosa was obtained by dissecting out the
whole length of the small intestine, washing
through the lumen with 10 ml of ice-cold
PBS and expelling the mucosa by gently
stroking the outer surface with a glass rod.
The mucosal material collected was washed
twice by centrifugation at 600 g at 4°C and
resuspension in ice-cold PBS. After the second
wash, as much fluid as possible was removed,
the tissue weighed and a 10% w/v homogenate
made as for tumour and liver above.
Marrow cells were wvashed twice by centri-
fugation at 4°C and resuspension in ice-cold
PBS. As much fluid as possible was then
removed, the pellet weighed and ice-cold dis-
tilled water added to give 10% w/v. The homo-
genate of marrow cells was prepared by
ultrasonication. Single-cell suspensions of in
vitro cultured HT29R were prepared from
log phase monolayer cultures by trypsinisa-
tion (trypsin 0-125% w/v, EDTA 0-01%0 w/v
in Hanks' BSS for 10 min at 37°C). Organelle-
free tumour-cell supernatant was prepared as
follows. Tumours were homogenized in 4 vol.
of cold 0-2 sucrose, using an all-glass homo-
genizer and diluted x 2 in sucrose to give a
10% w/v homogenate. This was centrifuged
for 1 h at 8000 g in a Sorvall RC-5B Super-
speed Centrifuge at 4°C. The supernatant was
collected and centrifuged for 1 h at 105,000 g
in an MSE Superspeed 65 Centrifuge at 4°C.
This second supernatant was collected and
analysed for enzyme activity, together writh
the original homogenate (see below).
Estimation of P-glucuronidase activity.-
/3-glucuronidase activity was estimated by a
modification ofthe method ofWorkman et al.
(1976), using p-nitrophenol-/-D glucuronide
(BDH) as substrate. A 100,ul homogenate was
incubated at 37°C with 100 ,ul of sodium
acetate-acetic acid buffer (0-2M) and 100 ,ul
p-nitrophenol glueuronide (NPG) solution.
The reaction was stopped with 2-2 ml
glycine-NaOH buffer (IM, pH 10-5) and thep-
nitrophenol released was estimated by absorp-
tion at 400 nm on a Beckman Model 25
spectrophotometer.
Controls were run in which buffer and
NPG were incubated together for the same
time as the test samples, but with the homo-
genate added after the glycine-NaOH buffer.
Protein concentration of the homogenates
was estimated by the Lowry method. After
subtraction of its blank control, the absorp-
tion of the test sample was compared to that
of a p-nitrophenol standard, and the enzyme
activity calculated as Htmol of p-nitrophenol
released/min/g protein. Progress curves were
linear over the assay period and the extent of
the reaction was proportional to the amount
of added enzyme (see Results). The effects of
pH and substrate concentration on enzyme
activity were investigated, and comparisons
made under optimal conditions for each
tissue. /-glucuronidase activity in whole cells
was estimated by re-suspension of in vitro
HT29R cells in Hank's BSS without phenol
red, supplemented with 500 heat-inactivated
FCS. The BGH substrate (10 mM) was made
up in the same medium. Cell viability by
trypan blue exclusion w%vas tested at each time
point of enzyme assay throughout the
experiment. The reaction was stopped by
glycine-NaOH buffer and p-nitrophenol re-
leased measured as described above.
RESULTS
Prior to the comparison of P-glucuro-
nidase levels in HT29R tumours and
normal mouse tissues, the optimal assay
conditions for this enzyme were defined
for both normal and immuno-suppressed
male CBA mice. ThepHoptimawerefound
to be 4-2 for liver, 4 0 for marrow, 5 2 for
small-intestinal mucosa and 3 3 for
HT29R.
The effect of substrate concentration on
enzyme activity for tumour and normal
tissues from immuno-suppressed mice is
shown in Fig. 1. A substrate concentra-
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Fia. 1.-Substrate dependence of immuno-suppressed CBA mouse tissues. [V]=p-nitrophenol released
( tmol/min/g protein). [S] =concentration ofp-nitrophenol glucuronide (NPG) (mM).
TABLE.-The /3-glucuronidase activity in homogenates of hetero-transplanted HT29R
tumours and host mouse tissues. (mean of 4 individual mice + 2 s.e.)
,-Glucuronidase activity
(Lmol p-nitrophenol released/min/g protein)
Liver
Small-intestinal mucosa
Marrow
HT29R in vivo
tion of 10 mm NPG was close to optimal
for all tissues, and was chosen for subse-
quent experiments. Fig. 2 shows that
progress curves were linear up to 80 min,
and that the quantity of product released
was proportional to the amount of homo-
genate in the assay. When P-glucuronidase
activity in homogenates of normal tissues
of immuno-suppressed and non-immuno-
suppressed mice were compared (Table), it
was noted that there was a higher activity
in the marrow ofimmuno-suppressed mice.
The marrow of nude mice showed even
higher enzyme activity. Enzyme activity
in liver and small-intestinal mucosa was
similar in normal, immuno-suppressed
CBA, and nude mice. The activity of
HT29R tumour homogenates grown in
immuno-suppressed mice was 42 x that
Normal CBA
mouse Immuno-
(pre-immuno- suppressed
suppression) CBA mouse
3-18+0-46 3-22+0-32
2-66+0-20 2-10+0-28
2-89+0-16 3-72+0-44
13-99+0-42
Nude
mouse
3-64+0-43
1 77+ 0 33
5-07+0-42
13 -00+ 0 85
of the host liver, 6-8 x that of the small
intestinal mucosa and 3 6 x that of the
marrow. The enzyme activity of the
HT29R tumour grown in nude mice was
very similar to that in immuno-suppressed
CBA mice and was 3-6 x that ofthe nude-
mouse liver, 7'3 x that of the small-
intestinal mucosa but only 2-6 x that of
the marrow. Tumour 3-glucuronidase
activity was reproducibly high in all
experiments.
Analysis of organelle-free extracts of
tumours grown in immuno-suppressed
CBA mice showed that only 16-19% of
/3-glucuronidase activity was present in
the cytosol, the remainder being associ-
ated with particulate fractions. To test
whether or not the /3-glucuronidase acti-
vity measured in homogenates and cell
10.0
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FIG. 2.-Progress curves of immuno-suppressed CBA mice for action of glucuronidase as NPG substrate.
0 1% w/v homogenate; A 200 w/v homogenate; * 5% w/v homogenate; * 10% w/v homogenate.
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FIG. 3.-fi-glucuronidase activity of intact
HT29R cells (each point represents dupli-
cate estimations). * 106 cells; 5+ 105
cells.
fractions ofwhole tumours was likely to be
available under normal physiological con-
ditions, intact in vitro HT29R cells were
incubated with NPG substrate. Fig. 3
shows that intact cells were capable of
releasing free p-nitrophenol from its sub-
strate. During the experiment there was
no impairment of cell viability for 3 h.
Fig. 4 shows in vivo growth curves of
control HT29R tumours and those treated
with maximum tolerated doses of cyclo-
phosphamide (180 mg/kg) and AM (35
mg/kg). Neither had much effect, and the
growth inhibition with AM (RTVT - 50 o
of control tumours at 12 days) was less
than with cyclophosphamide. Fig. 5
shows that the in situ response of HT29R
to AM (35 mg/kg) was no greater than
that seen with its p-methyl analogue
Relative
tumour
volume
Time after treatment (days)
FIG. 4. 1n1 8itu response of HT29R to AM
and cyclophosphamide. solvent control;
* AM (aniline mustard) 35 mg/kg; cyclo-
phosphamide 180 mg/kg; vertical bars
indicate + 2 s.e.
3
p-nitrophenc
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(m MO)
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FIG. 5. In situ response of HT29R to AMI
and p-methyl AM. 0 solvent control;
A AM 35 mg/kg; A PMAMI (p-methyl AMI)
100 mg/kg. Vertical bars indicate + 2 s.e.
(100 mg/kg). Other experiments showed
that the in situ response to melphalan
(8 mg/kg) was no greater than that seen
with cyclophosphamide (data not shown).
The in vivo-in vitro cell-survival curve for
AM (Fig. 6) showed a large initial shoulder.
The steep part of the curve was not
obtained until after doses equal to or
greater than, the LD50 (53 mg/kg) were
given. Similar results were obtained with
melphalan and cyclophosphamide.
DISCUSSION
The proposed mechanism of selective
action of AM against f-glucuronidase-rich
tumours involves p-hydroxylation and
conjugation to the p-O-glucuronide in the
liver, followed by deconjugation by the
tumour enzyme, selectively releasing the
highly toxic p-hydroxyaniline mustard in
the tumour.
Despite f-glucuronidase levels which
were 3-6 x those of the host marrow,
6-8 x those of the host small-intestinal
mucosa and 4-2 x those of the host liver,
AM was no more effective in inhibiting
the growth of HT29R or affecting its cell
survival than p-methyl AM, a closely
related analogue which cannot be meta-
Surviving
fraction
Drug dose (mg/ kg)
Vie. 6. Jn vveo-ioi, vitro cell-survixal assay
of HT29R following treatment of host
mice with AlMl. 0 Exp. 1; 0 Exp. 2;
Animals weie treated 24 h before assay.
(urxve (dra-vn by eye.
bolized in the same way. AM was also no
more active than cyclophosphamide or
melphalan.
The enzyme activities in marrow and
small-intestinal mucosa were measured,
because these tissues are likely to be
critically important in toxicity due to
alkylating-agent damage. Activity in the
liver was determined because this organ
was used for comparison with tumours in
the originally reported experiments (Whis-
son & Connors, 1965a, b; Connors &
Whisson, 1966). The P-glucuronidase
levels for 2 mouse tumours described in
those experiments, the ADJ/PC5 and the
ADJ/PC6 plasma-cell tumours, were 5 x
the host liver. Both tumours were mark-
edly more sensitive to AM than to
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p-methyl AM, cyclophosphamide or mel-
phalan. Similarly, the HT67 mouse adeno-
carcinoma which could be cured bv single
doses of AM but was insensitive to
p-methyl AM, had fi-glucuronidase levels
in the tumour 4 x those in the liver (Double
& Wl'orkman, 19771. OIn the basis of these
experiments, the 4-fold higher levels of
f-glucuronidase activity in HT29R than
in host liver might have been expected to
confer a selective sensitivity to AM.
A number of explanations may be con-
sidered why this was not seen. Firstly,
the 3-glucuronidase levels detected in the
whole-tumour homogenate might reflect
levels in the mouse compartment of the
tumour rather than in the human com-
partment. This possibility has been
excluded in previously reported experi-
ments in w%rhich mouse and human cells
of disaggregated in vivo HT29R tumours
have been separated by differential ad-
herence to immunoglobulin-coated Petri
dishes (Wareniuis, 1.980a). In these experi-
ments selective enrichment for the
HT29R cells was associated with a con-
comitant increase in /-glucuronidase
activity. Secondly, although /-glucuroni-
dase activity may be demonstrable in
tumour homogenates, the enzyme may not
be physiologically available in an in vivo
tumour. Although intact HT29R in vitro
cells have been shown to be capable of
metabolizing the NPG substrate, the
results from ultracentrifugation suggest
that most of the /-glucuronidase activity
is associated with particulate cell com-
ponents and thus may not be readily
available to metabolize drugs. It is note-
worthy that in the sensitive ADJ/PC6
tumour the /-glucuronidase is present
in high levels in the cytosol (Double,
personal communication) and that the
clinical response to AM was greater in
tumours where the enzyme showed a
diffuse, rather than particulate, histoche-
mical distribution (Young et al., 1976).
Thirdly, it has been shown that for several
alkylating agents, including AM, the cell-
survival curve for HT29R has a wide
shoulder (Warenius & Bleehen, submitted);
the steep part of the curve is not reached
until drug doses exceed the LD50. Quite
large increases in intra-tumour drug con-
centration, if they occur within the range
of the shoulder, may thus produce only
small differences in cell survival.
Finally, we have observed that follow-
ing immuno-suppression of mice the
3-glucuronidase activity of the marrow
increases. This might reduce the maxi-
murn tolerated dose for AM in this
experimental situation, and if the same
effect did not apply to another alkylating
agent, the relative efficacy of the drugs
in the immuno-suppressed animal might
differ from that in normal mice. In our
experimental animals we noted that most
cytotoxic drugs were more toxic in the
immuno-suppressed mice than their nor-
mal counterparts, and this difference was
particularly marked for AM. A further
possibility is that the liver of the particu-
lar mice used in these experiments is
unable to convert AM to AM glucuronide.
We have no evidence that this might be
the case, and a drug such as cyclophos-
phamide, which requires hepatic micro-
somal activation, is clearly active against
tumours in these mice, particularly the
murine RIF tumour (Warenius et al.,
1980). H-owever, we are performing
further studies to detect the appearance
of AM glucuronide in bile after injection
of AM. It would also be of value to
observe the response of the PC6 tumour
growing in these same immuno-suppressed
mice.
The different enzyme levels in immuno-
suppressed as compared to normal mice
draws attention to a potential problem in
the investigation of drug activity in the
xenograft system. No explanation can at
present be given for the high /-glucuroni-
dase activity in immuno-suppressed
mnouse marrow. This may not be simply
the result of immuno-suppressive manipu-
lations such as radiation, because nude
mice were found to have even higher levels
of /-glucuronidase in their marrow.
The /-glucuronidase activity of human
marrow has not been measured yet, and it
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would be of interest to know whether the
value was closer to those of normal CBA
mice or immuno-suppressed mice.
We have thus demonstrated that des-
pite high /-glucuronidase activity, the
HT29R tumour does not show an en-
hanced response to AM. Whether the
possible explanations for the poor res-
ponse in this situation also apply to
tumours in the clinic will require further
investigation. The pro-drug approach con-
tinues to be used in the rational design of
selective anti-tumour agents (e.g. Carl et
al., 1980). Human tumour xenografts such
as the HT29R model system can offer an
opportunity to relate the activity of these
and other chemotherapeutic agents to the
biochemistry of the particular tumour
under investigation.
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